Skip to main content
Clinical Trials/DRKS00027061
DRKS00027061
Completed
Phase 2

Analysis of changes in the gut microbiome, and dosing of dopaminergic therapy under supplementation of short-chain fatty acids and prebiotics as dietary supplements in the context of PD - PRE-PD Study

BASF SE0 sites80 target enrollmentNovember 19, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
G20
Sponsor
BASF SE
Enrollment
80
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2021
End Date
October 24, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
BASF SE

Eligibility Criteria

Inclusion Criteria

  • 1\. age at PD: 18\-90 years
  • 2\. primary Parkinson's syndrome
  • 3\. moderate disease severity (stable daily levodopa dose 500\-850 mg daily)
  • 4\. full orientation to time, place and person
  • 5\. sufficient knowledge of German (able to give informed consent)
  • 6\. independent mobility without, with unilateral or bilateral walking assistance

Exclusion Criteria

  • 1\. poor general condition
  • 2\. pregnancy
  • 3\. severe concomitant disease or organ dysfunction (heart failure, NYHA stages III\-IV, severe respiratory failure (e.g., with resting dyspnea), irreversible multiorgan failure, sepsis, acute viral hepatitis)
  • 4\. serious previous diseases of the gastrointestinal tract
  • 5\. malignancy (current or history with current follow\-up/treatment)
  • 6\. illness or medical treatment incompatible with study participation (pending surgical procedure, etc.)
  • 7\. immunosuppressive therapy in the last 6 months (e.g. mitoxantrone, azathioprine, cyclophosphamide, MTX)
  • 8\. intake of antibiotics or metformin during the past 3 months
  • 9\. vegan dietary habits

Outcomes

Primary Outcomes

Not specified

Similar Trials